HER2-Negative Breast Cancer Pipeline Expands with 75+ Therapies from 70+ Companies
核心洞察
DelveInsight's latest pipeline report reveals over 70 companies are actively developing more than 75 therapeutic candidates for HER2-negative breast cancer (搜索) treatment.
Recent clinical trials include Washington University's Phase II study of PD 0332991 combined with anastrozole for early-stage ER+ breast cancer and MedSIR (搜索)'s Phase II trial investigating improved tolerance of sacituzumab govitecan.
Leading pipeline candidates include Genentech's Giredestrant (Phase III SERD), Inavolisib (Phase III PI3Kα (搜索) inhibitor), and CytomX's conditionally activated antibody-drug conjugate CX-2009.
The HER2-negative breast cancer (搜索) therapeutic landscape is experiencing unprecedented growth, with over 70 companies actively developing more than 75 pipeline therapies according to DelveInsight's comprehensive pipeline analysis. This robust development activity reflects the significant unmet medical need in treating breast cancers that do not overexpress the HER2 (搜索) protein, which represents the majority of breast cancer cases worldwide.
Recent Clinical Trial Developments
Several major clinical trials have launched in December 2025, signaling accelerated development in this therapeutic area. Washington University School of Medicine initiated a Phase II study investigating PD 0332991 in combination with anastrozole for early-stage ER+ HER2-negative breast cancer (搜索). The study aims to improve pathologic complete response rates compared to historical controls using single-agent aromatase inhibitors and reduce the number of patients with on-therapy Ki67 levels above 10%.
MedSIR (搜索) announced a Phase II clinical trial designed to improve tolerance of sacituzumab govitecan in patients with unresectable locally advanced or metastatic triple-negative breast cancer (搜索) (TNBC) or luminal breast cancer (搜索). The trial targets patients refractory to at least one, but no more than two, prior standard chemotherapy regimens.
Merck Sharp & Dohme LLC launched a pivotal Phase III randomized, open-label study evaluating Sac-TMT (Sacituzumab Tirumotecan, MK-2870) followed by carboplatin/paclitaxel versus chemotherapy, both in combination with pembrolizumab as neoadjuvant therapy. This study focuses on high-risk, early-stage triple-negative breast cancer (搜索) or hormone receptor-low positive/HER2-negative breast cancer (搜索) patients.
Leading Pipeline Candidates
Giredestrant (Genentech)
Giredestrant represents a novel approach as a selective estrogen receptor (搜索) degrader (SERD) targeting the estrogen receptor. This orally bioavailable small molecule competitively inhibits estrogen binding to the ER and has demonstrated the ability to restrain both wild-type and mutant ER behavior in preclinical models. The drug candidate is currently in Phase III development, positioning it as a potential first-in-class oral SERD for HER2-negative breast cancer (搜索) treatment.
Inavolisib (Genentech)
Inavolisib is an investigational small molecule designed to selectively inhibit mutant PI3Kα (搜索). Preclinical studies show potent selective inhibition of PI3Kα with increased potency against mutant PI3K cells compared to wild-type cells. The molecule binds to the ATP-binding site of PI3Kα, blocking phosphorylation of PIP2 to PIP3 and preventing downstream signaling. Notably, inavolisib specifically degrades the mutant form of PI3Kα, resulting in reduced pathway activity. The drug has advanced to Phase III development.
CX-2009 (CytomX Therapeutics)
CX-2009 (Praluzatamab ravtansine) represents an innovative conditionally activated antibody-drug conjugate approach. The therapy comprises a CD166 (搜索)-directed humanized monoclonal antibody conjugated to the maytansinoid DM4, a tubulin inhibitor. Utilizing CytomX's Probody® platform technology, the drug incorporates a masking peptide to cover and block the cellular binding region of the antibody, which is tethered via a protease-cleavable linker. This design aims to improve tumor selectivity and reduce systemic toxicity. The drug is currently in Phase II development.
H3B-6545 (H3 Biomedicine)
H3B-6545 is an oral, selective estrogen receptor (搜索) covalent antagonist (SERCA) for metastatic ER-positive, HER2-negative breast cancer (搜索). As a first-in-class small molecule, H3B-6545 demonstrates activity in tumor models harboring wild-type or mutant ERα. The drug's activity against ERα mutants resistant to standard therapy addresses a significant unmet medical need both as monotherapy and in combination with other breast cancer treatments. The candidate is in Phase II development.
RGT-419B (Regor Therapeutics)
RGT-419B represents a new generation CDK inhibitor with an optimized kinase activity spectrum. Non-clinical studies demonstrated that RGT-419B achieved full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 (搜索) inhibitors. The drug's tumor cell suppression was further enhanced when combined with a selective estrogen receptor (搜索) down-regulator or PI3K signaling pathway inhibitor. The therapy is currently in Phase I development.
Market Landscape and Company Involvement
The HER2-negative breast cancer (搜索) pipeline includes contributions from major pharmaceutical companies and emerging biotechnology firms. Leading companies include Genentech, CytomX Therapeutics, H3 Biomedicine (搜索), Regor Therapeutics (搜索), Immutep Limited, Merck & Co, Klus Pharma, Olema Pharmaceuticals, BeiGene, AstraZeneca, Janssen/Merck/GSK, Ono Pharmaceutical, Laekna Therapeutics, NanoMab, InSilico Medicine, TYK Medicine, Shanghai Pharmaceutical Group, Verastem Oncology, Allarity Therapeutics, Shenzhen Yangli Pharmaceutical Technology, and Phoenix Molecular Designs.
Therapeutic Diversity and Administration Routes
The pipeline demonstrates significant diversity in therapeutic approaches, with products categorized across various routes of administration including oral, parenteral, intravitreal, subretinal, and topical delivery methods. Molecule types span monoclonal antibodies, peptides, polymers, small molecules, and gene therapy approaches, reflecting the breadth of scientific approaches being pursued.
The comprehensive development activity across multiple therapeutic modalities and development stages suggests a maturing pipeline that could significantly impact treatment options for HER2-negative breast cancer (搜索) patients in the coming years. With breast cancer representing the world's most common cancer in women and 30% of early-stage patients subsequently experiencing distant metastasis, these pipeline developments address a critical medical need for improved therapeutic options.